Therefore, it is reasonable to infer that baricitinib, a JAK1/2 inhibitor, may also play an anti-fibrosis role in IPF patients infected with COVID-19, and baricitinib can be developed as a drug candidate to effectively prevent pulmonary fibrosis after COVID-19 infection. This evidence concerns the gene JAK1 and COVID-19.